BICO BICO Group AB (publ)
BICO Group AB (publ) provides hardware, laboratory automation, and software solutions in North America, Europe, Asia, and internationally. It operates through two segments: Life Science Solutions and Lab Automation. The Bioprinting segment offers 3D bioprinters and bioinks with a range of technologies for various applications, resolutions, and volume/speed requirements, as well as provides services focused on accelerating drug discovery and development. The Life Science Solutions segment supplies lab instrumentation, consumables and applications in cell culture, cell imaging, cell sorting, and sample preparation for different analytics, such as genomics, as well as offers instruments and solutions for the manufacturing of diagnostics, as well as consumables. The Lab Automation segment provides the proprietary and hardware-agnostic Green Button Go Suite software for connected workflows, as well as automation technology integration, and consulting and engineering services to design, build, and install automated laboratory systems. In addition, the company offers a range of services and consumables such as reagents, bioinks, plates, and tissue models. It serves pharma and biopharma, biotech, diagnostics, academia and research, and cosmetic industries. The company offers its products through sales organizations, as well as through distributor network. BICO Group AB (publ) was formerly known as Cellink AB (publ) and changed its name to BICO Group AB (publ) in August 2021. The company was incorporated in 2016 and is headquartered in Gothenburg, Sweden.…
Industry Peers
Medical DevicesKey Statistics
About BICO Group (STO: BICO)
›
BICO Group (STO: BICO) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 512 employees.
The shares were at 15.92 SEK on 19 November 2026, down 21.3% over 52 weeks. Its 52-week range is 12.94 SEK to 25.40 SEK: the price is 37.3% below the high and 23.0% above the low.
Its market capitalisation is 1.12B SEK.
BICO Group reports return on equity of -62.3%, an operating margin of -4.6% and revenue up 20.2% year over year.
Its debt exceeds its cash by 142.40M SEK, a debt-to-equity ratio of 0.74. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 2 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 31.50 SEK is 97.9% above the current price. The next earnings report is expected on 17 February 2027.